<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939703</url>
  </required_header>
  <id_info>
    <org_study_id>TRIMD FH 942699</org_study_id>
    <nct_id>NCT02939703</nct_id>
  </id_info>
  <brief_title>Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance</brief_title>
  <official_title>Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arizona State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to study the role of the gut microbiome in the development of obesity, and whether&#xD;
      we can change the microbiome's contribution to host energy balance through diet. We have&#xD;
      created a novel model that explicitly links the effects of microorganisms on human energy&#xD;
      balance and modeled weight change, and will use the power of metabolic ward studies to&#xD;
      measure small changes in energy absorption, total daily energy expenditure, and/or food&#xD;
      intake that affect long-term weight gain or loss. By integrating clinical measurements,&#xD;
      bioreactor experiments, and mathematical modeling, we will be able to describe&#xD;
      cause-and-effect mechanisms that will enable a quantification of the microbiota's&#xD;
      contribution to weight gain and inspire future studies on the interactions of diet, the gut&#xD;
      microbiome, and human physiology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Actual">July 23, 2019</completion_date>
  <primary_completion_date type="Actual">July 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint for the protocol is the within-participant difference in fecal energy (via chemical oxygen demand, COD) normalized to the total daily energy intake and to the non-metabolizable marker PEG [COD (kcal) / PEG (g)].</measure>
    <time_frame>Days 24-29 vs. Days 53-58</time_frame>
    <description>Comparison within subject of control diet versus microbiome enhancer diet.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Control Western diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will consume a control western diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microbiome Enhancer diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will consume an experimental microbiome enhancer diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.</description>
    <arm_group_label>Control Western diet</arm_group_label>
    <arm_group_label>Microbiome Enhancer diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to communicate meaningfully with the investigator and legally competent to&#xD;
             provide informed written consent&#xD;
&#xD;
          2. Age 18 - 45 years, inclusive&#xD;
&#xD;
          3. Weight stable (+/- 3 kg) during the 6 months prior to enrollment&#xD;
&#xD;
          4. BMI â‰¤ 30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of cardiovascular disease (unstable angina, myocardial infarction&#xD;
             or coronary revascularization within 6 months, clinically significant abnormalities on&#xD;
             EKG, presence of cardiac pacemaker, implanted cardiac defibrillator)&#xD;
&#xD;
          2. History of type 1 or type 2 diabetes&#xD;
&#xD;
          3. Bleeding disorders&#xD;
&#xD;
          4. Acute or chronic infections&#xD;
&#xD;
          5. Hepatitis and/or cirrhosis&#xD;
&#xD;
          6. Severe asthma or chronic obstructive pulmonary disease&#xD;
&#xD;
          7. Renal insufficiency or nephritis&#xD;
&#xD;
          8. Thyroid dysfunction (suppressed TSH, elevated TSH if symptomatic, elevated thyroid&#xD;
             stimulating hormone (TSH) if asymptomatic)&#xD;
&#xD;
          9. Uncontrolled hypertension (BP &gt;160 mmHg systolic or &gt;100 mmHg diastolic)&#xD;
&#xD;
         10. Prior bariatric surgery&#xD;
&#xD;
         11. Inflammatory bowel disease or malabsorption, swallowing disorders, suspected or known&#xD;
             strictures, fistulas or physiological/mechanical GI obstruction, history of&#xD;
             gastrointestinal surgery, Crohn's disease or diverticulitis&#xD;
&#xD;
         12. Participants with strict dietary concerns (e.g. vegetarian or kosher diet, multiple&#xD;
             food allergies, or allergies to food we will provide them during the study)&#xD;
&#xD;
         13. Current use of polyethylene glycol (e.g. Dulcolax, Miralax, Gavilax)&#xD;
&#xD;
         14. Cancer within the last 3 years (except non-melanoma skin cancer or treated cervical&#xD;
             carcinoma in situ)&#xD;
&#xD;
         15. History of depression within &lt; 5 years from screening visit or which, in the opinion&#xD;
             of a medical investigator, will impact the participant's ability to complete the study&#xD;
&#xD;
         16. History of eating disorders&#xD;
&#xD;
         17. Cushing's disease or syndrome&#xD;
&#xD;
         18. Untreated or inadequately controlled hypo- or hyperthyroidism&#xD;
&#xD;
         19. Active rheumatoid arthritis or other inflammatory rheumatic disorder&#xD;
&#xD;
         20. Pregnant or nursing females or females less than 6 months postpartum from the&#xD;
             scheduled date of collection.&#xD;
&#xD;
         21. Tobacco use within the past 3 months&#xD;
&#xD;
         22. Metal implants (pace-maker, aneurysm clips) based on Investigator's judgment at&#xD;
             Screening.&#xD;
&#xD;
         23. Unable to participate in MRI or MRS assessments due to physical limitations of&#xD;
             equipment tolerances (e.g. MRI bore size) based on Investigator's judgment at&#xD;
             Screening.&#xD;
&#xD;
         24. Unable to tolerate MRI/MRS imaging or claustrophobia.&#xD;
&#xD;
         25. Nickel allergy.&#xD;
&#xD;
         26. Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4&#xD;
             weeks prior to the pretrial (screening) visit.&#xD;
&#xD;
         27. Intolerance to acetaminophen use.&#xD;
&#xD;
         28. History of regular alcohol consumption exceeding 7 drinks/week for female participants&#xD;
             or 14 drinks/week for male participants (1 drink = 5 ounces [150 mL] of wine or12&#xD;
             ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months before&#xD;
             screening.&#xD;
&#xD;
         29. Anemia (hemoglobin &lt;12 g/dl in men, &lt;11 g/dl in women)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven R Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosa Krajmalnik-Brown, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator at Arizona State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tri-md.org/</url>
    <description>Translational Research Institute for Metabolism and Diabetes</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adipose tissue</keyword>
  <keyword>calorimetry</keyword>
  <keyword>energy expenditure</keyword>
  <keyword>microbiome</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02939703/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

